Prof. Avner Yayon, Ph.D. , M.D., Founder and CEO
Prof. Yayon is a pioneer and a leading scientist in the fields of polypeptide growth factors, the extracellular matrix and the mechanisms underlying human skeletal disorders. He was the scientific founder of ProChon Biotech Ltd., and served as its President and CSO since its inception in 1996, focusing on the molecular mechanisms underlying FGF-related genetic and acquired skeletal disorders and the development of its advanced cartilage regeneration system, BioCart™II .
Prof. Yayon received his Ph.D. and M.D. degrees at the Hebrew University and Hadassah Medical School in Jerusalem. He subsequently served as a Research Associate at the department of surgical research, Harvard Medical School, and was a scientist and Associate Professor of Molecular Cell Biology at the Weizmann Institute of Science.
Dr. Ezequiel Wexselblatt, Ph.D. R&D Manager
Dr. Ezequiel Wexselblatt has served as the R&D Manager at Procore since January 2016.
Prior to joining ProCore, Dr. Wexselblatt served as a Fulbright research fellow at the University of California, San Diego, studying molecular transporters for cellular delivery and uptake of enzymes/drugs targeting liposomal vehicles to the lysosome, restoring enzymatic activity in diseased cells.
As a post-doctoral fellow at the Institute for Drug Research in the Hebrew University of Jerusalem, he developed novel multifunctional anticancer platinum drugs and explored their mechanism of activation and stability.
Dr. Wexselblatt received his Ph.D in Medicinal Chemistry at the Hebrew University of Jerusalem where he designed and synthesized small molecule inhibitors of key bacterial enzyme as novel targets for antibacterial agents.
Dr. Meital Ben-Dayan Bloch Ph.D. New Product Development – Project Manager
Dr. Ben-Dayan Bloch leads new product characterization and optimization at Procore.
Prior to joining ProCore, Dr. Ben-Dayan Bloch served as the research manager of a multidisciplinary joint research program between the Hebrew University in Jerusalem and the Sheba Medical Center in Ramat Gan, designing a novel diagnostic platform for tracing residual malignant tissues in cytoreductive surgery.
Dr. Ben-Dayan Bloch received her Ph.D. from the Institute for Drug Research, Faculty of Medicine at the Hebrew University of Jerusalem. Working on early diagnosis of colon cancer malignancy she mastered state of the art technologies in molecular and cellular biology.
Eilat Bain – Production and Operation Manager
Eilat serves as the Production and Operation Manager at Procore.
Prior to joining Procore, Eilat served as Director of Operations at Hemostemix Ltd since 2013. Beforehand, she led the cell therapy unit at Macrocure Ltd. and at Theravitae Ltd. since 2006. Eilat has extensive experience in product development and operations, transfer of technology and production from Israel to new manufacturing sites in the US and Europe. While working at Macrocure she established the Manufacturing Department in Israel. She also led the technology transfer of the manufacturing to US contract manufacturer in preparations for conducting a Phase III cell therapy clinical trials. Eilat received a BSc. degree in biology from the Hebrew University in Jerusalem.